Avantogen's Proprietary Adjuvant, GPI-0100, to Be Presented to International Vaccine Meeting; Structure-Activity Relations of Im

Avantogen (ASX:ACU) today announced the acceptance of a
scientific paper entitled, "Synergistic Effects of Immune Agonists on
Efficacy of Vaccines" for the 20th Annual Meeting of the International
Society for Biological Therapy of Cancer. The meeting will be held
November 11 - 13, 2005, at the Hilton Alexandria Mark Center,
Alexandria, VA, and focuses on the prevailing issues in immunology and
biological therapy of cancer. Dante Marciani, Ph.D., Avantogen's Chief
Scientist, Immunotherapy, will present the Poster to the attending
scientists. The abstract of the presentation will be published in the
November/December 2005 issue of the Journal of Immunotherapy.
   Avantogen CEO, Dr. Leonard Firestone, observed: "GPI-0100, a
saponin derivative, is an extremely effective, non-toxic, highly
stable immune booster that demonstrably improves the immune response
to antigens in a great variety of vaccines (for example, see Slovin et
al's publication in the January 2005 issue of Vaccine). The head of
Avantogen's programs, Dr. Marciani, is a world authority on vaccine
agonist structure-activity relations, as well as GMP manufacture. Dr.
Marciani has recently overseen our Company's involvement in several
human cancer vaccine trials, and is now broadening GPI-0100's
application to infectious disease vaccines as well. Dr. Marciani and
Avantogen are actively seeking new collaborations with both types of
vaccine developers/manufacturers. This acceptance by a peer review
conference further validates our confidence in this adjuvant."

   About Avantogen

   Avantogen (formerly Australian Cancer Technology) is an
international biotechnology company developing a broad
oncology-related product portfolio. Avantogen is developing RP101, an
exceptionally promising pancreatic cancer drug currently in Phase II
clinical studies, through a joint venture with Bioaccelerate of New
York. Avantogen's Pentrys(TM) anti-cancer vaccine is undergoing Phase
IIb clinical trials in prostate cancer patients, and the Company is
advancing a family of immune-enhancing adjuvants which has been in
three Phase I cancer trials in the United States. The company has also
marketed Revisys(TM), a branded line of medical nutritionals
specifically developed to address special nutritional needs, such as
those following cancer treatments. Avantogen is traded on the
Australian Stock Exchange (ASX) under the symbol ACU. The Company has
established a Level 1 ADR stock program in the U.S. trading under the
symbol AUCJY and also is listed on the Xetra exchange, the electronic
trading system of the Frankfurt Stock Exchange, trading under the
symbol CBS.

   Forward-Looking Statements

   Statements contained in this press release that are not historical
information are forward-looking statements as defined within the
Private Securities Litigation Reform Act of 1995. Such forward-looking
statements are subject to risks and uncertainties that could cause
Avantogen's ("company") actual results to differ materially from those
projected or implied. Such potential risks and uncertainties relate,
but are not limited, to the results of clinical trials, product demand
and market acceptance, the impact of competitive products and pricing,
effectiveness and pace of current and future product development, and
regulatory approval. More detailed information on these and additional
factors that could affect the company's operating and financial
results are described in the company's annual reports filed or to be
filed with the Australian Stock Exchange. The company urges all
interested parties to read these reports to gain a better
understanding of the many business and other risks that the company
faces. The historical results achieved by the company are not
necessarily indicative of its future prospects. The company undertakes
no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise.